Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viramune in HIV-infected patients on stable nucleoside therapy
NCT00002368Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Viramune Arm with Placebo Arm (2 arms). Primary endpoint: Time to first clinical AIDS progression event or death at 24 months. Status: completed.
02
Drugs
nevirapine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002368.